$ALC

Alcon Inc. (ALC) priced a EUR 500 million offering of 3.875% senior notes due 2033. The proceeds will be used for general corporate purposes, including potential debt refinancing. The offering is expected to close on September 2, 2026, subject to customary conditions.

Alcon Inc. (ALC) reported Q2 2026 net sales of $2.782B, up 8% YoY. Surgical sales rose 8%, with Equipment/Other up 26% but Implantables up only 1%. Vision Care sales increased 8%, driven by contact lenses and ocular health products. Reported operating margin fell to 0.4% due to a $402M charge, but core margin improved to 20.6%. Management maintained sales growth outlook at 5-7% but raised core EPS growth guidance to 12-15%.

Bill Ackman's Pershing Square raised $5B for a new fund, PSUSA, investing 95% of it. Ackman exited Alphabet, Universal Music Group, and Hertz, adding Visa, Mastercard, Netflix, S&P Global, Intercontinental Exchange, and Alcon. He also plans a private investment fund, Pershing Square Ventures, to gain insights into tech and private companies.

Pershing Square Holdings highlighted Alcon (ALC) as a new position in its Q2 2026 investor letter, citing its leading position in ophthalmology and long-term growth prospects. Alcon closed at $73.55 per share on August 18, 2026, with a market cap of $37.14 billion. The company has shown a 9.21% one-month return and a 9.24% loss over 52 weeks.

Deutsche Bank raised its target price for Alcon to 73 Swiss francs from 70 and kept a buy rating, citing strong operational execution and solid Q2 results. It said headwinds in the intraocular lens segment are offset by momentum in other businesses and confidence in reaching at least the midpoint of its annual target range. Alcon shares fell over 2% on the day.

Alcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.

Pershing Square Holdings, managed by Bill Ackman, initiated new positions in Netflix and five other stocks in Q2 after a sell-off. According to Pershing’s interim report, Netflix shares were bought after a 50% drop from June 2025 highs and a valuation de-rating. Other buys were Visa, Mastercard, S&P Global, Intercontinental Exchange, and Alcon, amid AI-disruption concerns.

Pershing Square’s Q2 update says Bill Ackman’s Pershing Square USA (PSUS) raised a $5 billion IPO and has deployed over 95% of PSUS capital across 14 investments, including new positions in Visa, Mastercard, Intercontinental Exchange, Netflix, Alcon and S&P Global. The article lists Q2 2026 holdings and notes Ackman’s long-term return goal above 20% gross annually.

Alcon reported Q2 2026 results showing higher sales and revenue but lower net income, according to the company. It kept 2026 net sales growth guidance and noted a collaboration with RxSight. Analysts cited a CHF76.62 fair value versus a CHF59.48 close and highlighted product launches and recent acquisitions, while valuation metrics showed a 54.9x P/E versus industry averages.

Simply Wall St discusses Alcon’s Q2 2026 earnings, saying sales and revenue rose but net income fell, while 2026 net sales growth guidance was maintained. It also cites a RxSight collaboration and notes Alcon’s shares returned 17.97% over 90 days but -13.93% over one year. A “fair value” of CHF76.62 vs CHF59.48 is referenced.